Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

Oncogene volume 30, pages 1963–1968 (2011)Cite this article

Subjects

Abstract

Non-small-cell lung cancer (NSCLC) is the most deadly type of cancer in the United States and worldwide. Although new therapy is available, the survival rate of NSCLC patients remains low. One hallmark of cancer cells is defects in the apoptotic cell death program. In this study, we investigate the role of B-cell lymphoma 2 (Bcl-2) family members Bcl-2, Bcl-xL and Mcl-1, known to regulate cell survival and death, in a panel of fourteen NSCLC cell lines. NSCLC cell lines express high levels of Mcl-1 and Bcl-xL, but not Bcl-2. Silencing the expression of Mcl-1 with small interfering RNA (siRNA) oligonucleotides potently killed a subgroup of NSCLC cell lines. In contrast, Bcl-xL siRNA had no effect in these lines unless Mcl-1 siRNA was also introduced. Interestingly, high MCL1 to BCL-xl messenger RNA determines whether the cells depend on Mcl-1 for survival. We further investigated the role of Mcl-1 in NSCLC cells using a Mcl-1-dependent cell line, H23. The expression of a complementary DNA containing only the coding region of MCL1 rescued H23 cells from the toxicity of a 3′ untranslated region (UTR) targeting Mcl-1 siRNA but not a siRNA targeting the coding region of MCL1. Furthermore, we show that Mcl-1 sequesters the BH3-only protein Noxa and Bim and the apoptotic effector Bak. Not surprisingly, Noxa, Bim, or Bak knockdown partially rescued H23 cells from toxicity mediated by Mcl-1 siRNA to different degrees. Collectively, our results indicate that targeting Mcl-1 may improve therapy for a subset of NSCLC patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Akgul C . (2009). Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 66: 1326–1336.

    Article  CAS  PubMed  Google Scholar 

  • Berrieman HK, Smith L, O'Kane SL, Campbell A, Lind MJ, Cawkwell L . (2005). The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes. Cancer 103: 1415–1419.

    Article  CAS  PubMed  Google Scholar 

  • Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA et al. (1999). Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 79: 952–958.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393–403.

    Article  CAS  PubMed  Google Scholar 

  • Chen S, Dai Y, Harada H, Dent P, Grant S . (2007). Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67: 782–791.

    Article  CAS  PubMed  Google Scholar 

  • Cory S, Huang DC, Adams JM . (2003). The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590–8607.

    Article  CAS  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA . (2000). The hallmarks of cancer. Cell 100: 57–70.

    Article  CAS  PubMed  Google Scholar 

  • Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE, Tron VA . (2009). RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One 4: e6651.

    Article  PubMed  PubMed Central  Google Scholar 

  • Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ . (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183–192.

    Article  CAS  PubMed  Google Scholar 

  • Leu JI, Dumont P, Hafey M, Murphy ME, George DL . (2004). Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6: 443–450.

    Article  CAS  PubMed  Google Scholar 

  • Li J, Viallet J, Haura EB . (2008). A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol 61: 525–534.

    Article  CAS  PubMed  Google Scholar 

  • Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA et al. (2007). ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26: 3972–3979.

    Article  CAS  PubMed  Google Scholar 

  • Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S . (2009). Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 6: 352–366.

    Article  CAS  PubMed  Google Scholar 

  • Minna JD, Roth JA, Gazdar AF . (2002). Focus on lung cancer. Cancer Cell 1: 49–52.

    Article  CAS  PubMed  Google Scholar 

  • Reed JC, Doctor KS, Godzik A . (2004). The domains of apoptosis: a genomics perspective. Sci STKE 2004: re9.

    PubMed  Google Scholar 

  • Rodenhuis S, Slebos RJ . (1992). Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52: 2665s–22669s.

    CAS  PubMed  Google Scholar 

  • Song L, Coppola D, Livingston S, Cress D, Haura EB . (2005). Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 4: 267–276.

    Article  CAS  PubMed  Google Scholar 

  • Sun S, Schiller JH, Spinola M, Minna JD . (2007). New molecularly targeted therapies for lung cancer. J Clin Invest 117: 2740–2750.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC et al. (2008). Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27: 6646–6656.

    Article  CAS  PubMed  Google Scholar 

  • Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J et al. (2007). Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 67: 1176–1183.

    Article  CAS  PubMed  Google Scholar 

  • Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421–3428.

    Article  CAS  PubMed  Google Scholar 

  • Wesarg E, Hoffarth S, Wiewrodt R, Kroll M, Biesterfeld S, Huber C et al. (2007). Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 121: 2387–2394.

    Article  CAS  PubMed  Google Scholar 

  • Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. (2005). Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294–1305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. (2007). Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856–859.

    Article  CAS  PubMed  Google Scholar 

  • Zhai D, Jin C, Huang Z, Satterthwait AC, Reed JC . (2008). Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem 283: 9580–9586.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang B, Gojo I, Fenton RG . (2002). Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99: 1885–1893.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank members of the Leverson laboratory for helpful discussions.

Author information

Authors and Affiliations

  1. Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA

    H Zhang, S Guttikonda, L Roberts, T Uziel, D Semizarov, S W Elmore, J D Leverson & L T Lam

Authors
  1. H Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Guttikonda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Uziel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Semizarov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S W Elmore
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J D Leverson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L T Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L T Lam.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, H., Guttikonda, S., Roberts, L. et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 30, 1963–1968 (2011). https://doi.org/10.1038/onc.2010.559

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.559

Keywords

This article is cited by

Search

Advanced search

Quick links